Literature DB >> 33008875

Adiposity and Endometrial Cancer Risk in Postmenopausal Women: A Sequential Causal Mediation Analysis.

Vivian Viallon1, Laure Dossus1, S Ghazaleh Dashti2,1,3, Dallas R English4,5, Julie A Simpson4, Amalia Karahalios4,6, Margarita Moreno-Betancur3,7, Carine Biessy1, Sabina Rinaldi1, Pietro Ferrari1, Anne Tjønneland8, Jytte Halkjær8, Christina C Dahm9, Helene Tilma Vistisen9, Florence Menegaux10, Vittorio Perduca11, Gianluca Severi10,12,13, Krasimira Aleksandrova14,15, Matthias B Schulze15,16, Giovanna Masala17, Sabina Sieri18, Rosario Tumino19, Alessandra Macciotta20, Salvatore Panico21, Anouk E Hiensch22, Anne M May22, J Ramón Quirós23, Antonio Agudo24, Maria-Jose Sánchez25,26,27,28, Pilar Amiano27,29, Sandra Colorado-Yohar27,30,31, Eva Ardanaz27,32,33, Naomi E Allen34, Elisabete Weiderpass1, Renée Turzanski Fortner35, Sofia Christakoudi36,37, Konstantinos K Tsilidis36,38, Elio Riboli36, Rudolf Kaaks35, Marc J Gunter1.   

Abstract

BACKGROUND: Adiposity increases endometrial cancer risk, possibly through inflammation, hyperinsulinemia, and increasing estrogens. We aimed to quantify the mediating effects of adiponectin (anti-inflammatory adipocytokine); IL6, IL1-receptor antagonist, TNF receptor 1 and 2, and C-reactive protein (inflammatory status biomarkers); C-peptide (hyperinsulinemia biomarker); and free estradiol and estrone (estrogen biomarkers) in the adiposity-endometrial cancer link in postmenopausal women.
METHODS: We used data from a case-control study within the European Prospective Investigation into Cancer and Nutrition (EPIC). Eligible women did not have cancer, hysterectomy, and diabetes; did not use oral contraceptives or hormone therapy; and were postmenopausal at recruitment. Mediating pathways from adiposity to endometrial cancer were investigated by estimating natural indirect (NIE) and direct (NDE) effects using sequential mediation analysis.
RESULTS: The study included 163 cases and 306 controls. The adjusted OR for endometrial cancer for body mass index (BMI) ≥30 versus ≥18.5-<25 kg/m2 was 2.51 (95% confidence interval, 1.26-5.02). The ORsNIE were 1.95 (1.01-3.74) through all biomarkers [72% proportion mediated (PM)] decomposed as: 1.35 (1.06-1.73) through pathways originating with adiponectin (33% PM); 1.13 (0.71-1.80) through inflammation beyond (the potential influence of) adiponectin (13% PM); 1.05 (0.88-1.24) through C-peptide beyond adiponectin and inflammation (5% PM); and 1.22 (0.89-1.67) through estrogens beyond preceding biomarkers (21% PM). The ORNDE not through biomarkers was 1.29 (0.54-3.09). Waist circumference gave similar results.
CONCLUSIONS: Reduced adiponectin and increased inflammatory biomarkers, C-peptide, and estrogens mediated approximately 70% of increased odds of endometrial cancer in women with obesity versus normal weight. IMPACT: If replicated, these results could have implications for identifying targets for intervention to reduce endometrial cancer risk in women with obesity. ©2020 American Association for Cancer Research.

Entities:  

Year:  2020        PMID: 33008875     DOI: 10.1158/1055-9965.EPI-20-0965

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  5 in total

Review 1.  Metabolic dysfunction and obesity-related cancer: Beyond obesity and metabolic syndrome.

Authors:  Sheetal Hardikar; Mary C Playdon; Prasoona Karra; Maci Winn; Svenja Pauleck; Alicja Bulsiewicz-Jacobsen; Lacie Peterson; Adriana Coletta; Jennifer Doherty; Cornelia M Ulrich; Scott A Summers; Marc Gunter
Journal:  Obesity (Silver Spring)       Date:  2022-07       Impact factor: 9.298

2.  Pan-cancer analysis of pre-diagnostic blood metabolite concentrations in the European Prospective Investigation into Cancer and Nutrition.

Authors:  Marie Breeur; Pietro Ferrari; Laure Dossus; Mazda Jenab; Mattias Johansson; Sabina Rinaldi; Ruth C Travis; Mathilde His; Tim J Key; Julie A Schmidt; Kim Overvad; Anne Tjønneland; Cecilie Kyrø; Joseph A Rothwell; Nasser Laouali; Gianluca Severi; Rudolf Kaaks; Verena Katzke; Matthias B Schulze; Fabian Eichelmann; Domenico Palli; Sara Grioni; Salvatore Panico; Rosario Tumino; Carlotta Sacerdote; Bas Bueno-de-Mesquita; Karina Standahl Olsen; Torkjel Manning Sandanger; Therese Haugdahl Nøst; J Ramón Quirós; Catalina Bonet; Miguel Rodríguez Barranco; María-Dolores Chirlaque; Eva Ardanaz; Malte Sandsveden; Jonas Manjer; Linda Vidman; Matilda Rentoft; David Muller; Kostas Tsilidis; Alicia K Heath; Hector Keun; Jerzy Adamski; Pekka Keski-Rahkonen; Augustin Scalbert; Marc J Gunter; Vivian Viallon
Journal:  BMC Med       Date:  2022-10-19       Impact factor: 11.150

3.  Identifying molecular mediators of the relationship between body mass index and endometrial cancer risk: a Mendelian randomization analysis.

Authors:  Emma Hazelwood; Eleanor Sanderson; Vanessa Y Tan; Katherine S Ruth; Timothy M Frayling; Niki Dimou; Marc J Gunter; Laure Dossus; Claire Newton; Neil Ryan; Dimitri J Pournaras; Tracy A O'Mara; George Davey Smith; Richard M Martin; James Yarmolinsky
Journal:  BMC Med       Date:  2022-04-19       Impact factor: 11.150

4.  Adiposity and breast, endometrial, and colorectal cancer risk in postmenopausal women: Quantification of the mediating effects of leptin, C-reactive protein, fasting insulin, and estradiol.

Authors:  S Ghazaleh Dashti; Julie A Simpson; Vivian Viallon; Amalia Karahalios; Margarita Moreno-Betancur; Theodore Brasky; Kathy Pan; Thomas E Rohan; Aladdin H Shadyab; Cynthia A Thomson; Robert A Wild; Sylvia Wassertheil-Smoller; Gloria Y F Ho; Howard D Strickler; Dallas R English; Marc J Gunter
Journal:  Cancer Med       Date:  2022-01-20       Impact factor: 4.452

Review 5.  Adipocytokines and disease progression in endometrial cancer: a systematic review.

Authors:  Irene Ray; Lisiane B Meira; Agnieszka Michael; Patricia E Ellis
Journal:  Cancer Metastasis Rev       Date:  2021-12-24       Impact factor: 9.264

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.